HIGHLIGHTS
- What: This study evaluated the first-line combination of atezolizumab and etoposide and demonstrated a significant improvement in overall survival rates despite more irAEs .
- Who: Junyu Qiu and collaborators from the Queen Mary School, Medical Department, Nanchang University, Nanchang, China have published the Article: Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment, in the Journal: (JOURNAL)
- Future: Research and development efforts are necessary to overcome these constraints and ensure continued progress. Investigations are required to comprehensively understand acquired and primary resistance particularly in the context . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.